Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer recaps on its RXC007 programme - a drug which has potential for development in multiple fibrotic conditions. He says they're currently carrying out manufacturing work and safety studies to build the regulatory package that should allow them to enter first in man clinical trials in the first half of 2021.
Redx Pharma looks ahead to first in man clinical trials of its fibrosis drug RXC007
Quick facts: Redx Pharma PLC
Price: 66.5 GBX
Market Cap: £129.84 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE